Patent ID: 9682143
Date: 2017-06-20
CPC Classifications: A61K,C07K

Claim:
1. A method of inducing a T-cell mediated immune response against a human cancer cell that expresses MUC5ac, or CEACAM5, comprising administering to a subject with a human cancer that expresses MUC5ac or CEACAM5 a leukocyte redirecting bispecific antibody comprising a first antibody or antigen-binding fragment thereof that binds to human CD3 and a second antibody or antigen-binding fragment thereof that binds to a human target antigen selected from the group consisting of MUC5ac, and CEACAM5; wherein administration of the bispecific antibody induces a leukocyte-mediated immune response against the cancer and wherein the bispecific antibody comprises: (i) a first antibody moiety conjugated to an AD (anchoring domain) moiety from an AKAP protein; and (ii) a second antibody moiety conjugated to a DDD (dimerization and docking domain) moiety, wherein the amino acid sequence of said DDD moiety is residues 1-44 of human protein kinase A (PKA) RIIα, and wherein two copies of the DDD moiety form a dimer that binds to one copy of the AD moiety to form the bispecific antibody.